Bio-Rad Labs (BIO) Tops Q3 EPS by 11c

Bio-Rad Labs (NYSE: BIO) reported Q3 EPS of $0.62, $0.11 better than the analyst estimate of $0.51. Revenue for the quarter came in at $508.7 million versus the consensus estimate of $480.6 million.

"We are pleased with a strong sales performance in the third quarter, in particular, our life science business, with nearly 20 percent currency-neutral growth," said Norman Schwartz, Bio-Rad President and Chief Executive Officer. "Continued investments in our operations have affected profitability for the first nine months of the year, but these investments are necessary to support our growth."

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
• Argus Starts SpaceX (SPCX) at Hold